Agreements reached under this partnership
Business Alliances- 1
Consideration of entering into a joint research agreement covering basic research, nonclinical studies, clinical trials and other activities directed toward regulatory approval
- 2
Verification of the feasibility of a new cancer treatment technology combining “Steboronin®” with “particle beams other than neutron beams”
These are items that the documents state the two companies will work on. The lines above and below represent arrangements between the two companies.
The impact of this matter on the Company’s results for the fiscal year ending March 2027 will be limited.
| Item | Details |
|---|---|
| Name of alliance partner | National Institutes for Quantum Science and Technology (QST), QST Hospital |
| Alliance partner's business activities | QST is a national research and development agency engaged in research and development relating to radiation medicine and quantum science and technology. QST Hospital provides radiation-based medical care, including heavy-ion cancer treatment, and conducts research and development. It operates particle research facilities. |
| Alliance partner's location | Chiba, Chiba Prefecture |
| Type of alliance | Business Alliances |
| Details of the alliance | Consideration of entering into a joint research agreement covering basic research, nonclinical studies, clinical trials and other activities directed toward regulatory approval, Verification of the feasibility of a new cancer treatment technology combining “Steboronin®” with “particle beams other than neutron beams” |
| Contract Date | 28 July 2026 |
| Impact on Business Performance | The impact of this matter on the Company’s results for the fiscal year ending March 2027 will be limited. |
Items this document does not state (16)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To assess the feasibility of a new cancer treatment technology by combining QST Hospital’s research infrastructure and expertise relating to particle research facilities and particle beams with the Company’s expertise in the research and development, manufacturing and regulatory affairs of boron-based pharmaceuticals.